Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
In patients with T2D and MASLD, SGLT2is did not show a lower risk of MLO compared with DPP4is. Clinicians should consider the overall patient conditions and the additional benefits of SGLT2is to support the decision to switch from DPP4is.
Authors
- Tsung‐Hua Shen (ORCID: https://orcid.org/0000-0003-0535-2171)
- Elizabeth S. Aby (ORCID: https://orcid.org/0000-0002-1809-2658)
- Joel F. Farley (ORCID: https://orcid.org/0000-0002-5196-5238)
- David M. Vock (ORCID: https://orcid.org/0000-0002-5459-9579)
Institutions
- University of Minnesota (US)
- University of Minnesota System (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1111/dom.15853
- Citations
- 9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.22